Daiichi Sankyo Company Management

Management Kriterienprüfungen 3/4

Daiichi Sankyo Company CEO ist Hiroyuki Okuzawa , ernannt in Apr 2023, hat eine Amtszeit von 3.08 Jahren. Die jährliche Gesamtvergütung beträgt ¥252.00M , bestehend aus 33.3% Gehalt und 66.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.003% der Aktien des Unternehmens, im Wert von $848.15K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.7 Jahre bzw. 2.4 Jahre.

Wichtige Informationen

Hiroyuki Okuzawa

Geschäftsführender

JP¥252.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	33.33%
Amtszeit als Geschäftsführer	3.1yrs
Eigentum des Geschäftsführers	0.003%
Durchschnittliche Amtszeit des Managements	2.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Hiroyuki Okuzawa im Vergleich zu den Einnahmen von Daiichi Sankyo Company verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2026	n/a	n/a	JP¥260b
Dec 31 2025	n/a	n/a	JP¥305b
Sep 30 2025	n/a	n/a	JP¥280b
Jun 30 2025	n/a	n/a	JP¥296b
Mar 31 2025	JP¥252m	JP¥84m	JP¥296b
Dec 31 2024	n/a	n/a	JP¥246b
Sep 30 2024	n/a	n/a	JP¥250b
Jun 30 2024	n/a	n/a	JP¥229b
Mar 31 2024	JP¥252m	JP¥84m	JP¥201b
Dec 31 2023	n/a	n/a	JP¥186b
Sep 30 2023	n/a	n/a	JP¥148b
Jun 30 2023	n/a	n/a	JP¥147b
Mar 31 2023	JP¥151m	JP¥51m	JP¥109b

Vergütung im Vergleich zum Markt: HiroyukiDie Gesamtvergütung ($USD1.58M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.84M).

Entschädigung vs. Einkommen: HiroyukiDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Hiroyuki Okuzawa (63 yo)

3.1yrs

Amtszeit

JP¥252,000,000

Vergütung

Mr. Hiroyuki Okuzawa is Chief Executive Officer of Daiichi Sankyo Company, Limited from April 1, 2025 and was its Chief Operating Officer until April 1, 2025. He is President of Daiichi Sankyo Company, Lim...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sunao Manabe	Executive Chairperson	11.9yrs	JP¥342.00m	0.0092% $ 2.8m
Hiroyuki Okuzawa	President	3.1yrs	JP¥252.00m	0.0028% $ 848.1k
Tomohiro Kodama	Senior Executive Officer	less than a year	keine Daten	keine Daten
Tetsuya Ohira	Corporate Officer	less than a year	keine Daten	keine Daten
Naoto Tsukaguchi	Senior Executive Officer	no data	keine Daten	keine Daten
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	2.3yrs	keine Daten	keine Daten
Takashi Matsumoto	Sr. Exec Ofcr	4.3yrs	keine Daten	0.0025% $ 748.2k
Joji Nakayama	Senior Adviser	5.9yrs	JP¥185.00m	keine Daten
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	no data	keine Daten	keine Daten
Stuart Mackey	Global Head of Business Development	no data	keine Daten	keine Daten
Thierry Gruson	Head of Global Oncology Marketing	no data	keine Daten	keine Daten
Kento Wada	Global Head of Clinical Safety & Pharmacovigilance Unit	no data	keine Daten	keine Daten

2.7yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrenes Management: DSKY.FDas Führungsteam des Unternehmens gilt als erfahren (2.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sunao Manabe	Executive Chairperson	11.9yrs	JP¥342.00m	0.0092% $ 2.8m
Hiroyuki Okuzawa	President	4.9yrs	JP¥252.00m	0.0028% $ 848.1k
Takashi Matsumoto	Sr. Exec Ofcr	1.9yrs	keine Daten	0.0025% $ 748.2k
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	1.3yrs	keine Daten	keine Daten
Shizuko Ueno	Senior Executive Officer	1.3yrs	keine Daten	keine Daten
Reiko Kinoshita	Independent Outside Director	less than a year	keine Daten	keine Daten
Akihiro Hiroshi Watanabe	Independent Outside Director	less than a year	keine Daten	keine Daten
Yo Honma	Independent Outside Director	1.9yrs	keine Daten	0.000050% $ 15.1k
Takaaki Nishii	Independent Outside Chairperson	2.9yrs	keine Daten	0.00016% $ 48.5k
Miyuki Arai	Full-time Member of Audit & Supervisory Board	2.9yrs	keine Daten	0.0011% $ 348.3k
Yukiko Imazu	Outside Audit & Supervisory Board Member	7.9yrs	keine Daten	keine Daten
Yasuhiro Komatsu	Independent Outside Director	3.9yrs	keine Daten	keine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: DSKY.FDie Vorstandsmitglieder gelten nicht als erfahren ( 2.4 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/22 20:18
Aktienkurs zum Tagesende	2026/05/22 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2026/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Daiichi Sankyo Company, Limited wird von 27 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Daiichi Sankyo Company Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Recent updates

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Suntory Holdings Limited signed a letter of intent to acquire Daiichi Sankyo Healthcare Co., Ltd. from Daiichi Sankyo Company, Limited (TSE:4568) for approximately ¥250 billion.

Daiichi Sankyo Company, Limited to Report Q4, 2026 Results on Apr 27, 2026

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Datroway Approves in Us for EGFRm Lung Cancer

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 17,000,000 shares, representing 0.91% for ¥50,000 million.

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited Provides Updated on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Daiichi Sankyo's Datopotamab Deruxtecan is Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd)

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO